Literature DB >> 2783444

IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.

J J Mulé1, J A Krosnick, S A Rosenberg.   

Abstract

The in vitro incubation of B6 splenocytes with purified, mouse rIL-4 for 4 to 5 days was sufficient to generate lymphokine-activated killer (LAK) activity. In addition, rIL-4 augmented LAK cytotoxic activity when combined with rIL-2, as measured in a 4 h 51Cr-release assay against fresh, syngeneic MCA-sarcoma (MCA-102 and MCA-105) cells. Interestingly, this augmentation was not observed against the cultured YAC-1 target. LAK generation and augmentation of cytotoxicity by rIL-4 was species-specific, because human rIL-4 (up to 20,000 U/ml) failed to elicit these effects in the mouse splenocyte cultures. When 5-day B6 LAK cells (splenocytes incubated in rIL-2 at 1000 U/ml for 5 days) were split and recultured in the combination of rIL-2 plus rIL-4 for 4 additional days at least a twofold greater expansion in cell number resulted compared to similar cells cultured in either rIL-2 or rIL-4 alone. Moreover, LAK cells expanded in rIL-2 plus rIL-4 exhibited substantial increases in in vitro cytolytic activity (on a per cell basis) against MCA-102 and MCA-105 sarcoma cells, but not against YAC-1 targets. FACS analysis or negative selection using Lyt-2 or NK-1.1 mAb plus C revealed no differences in effector phenotype(s) of LAK cells expanded in rIL-2 alone compared to rIL-2 plus rIL-4 to account for the differences observed in both expansion and cytolytic activity by rIL-4. The majority of cells was Thy-1+, Lyt-2+, T3+, and ASGM-1+. However, a marked increase in the granule-associated serine esterase, BLT-E, was found only in LAK cells expanded in the combination of both lymphokines. Collectively, these studies show that rIL-4 has potent regulatory activities on splenic LAK generation, expansion, and cytotoxic function in the mouse.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783444

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  In CD4+ T-cell-induced diabetes, macrophages are the final effector cells that mediate islet beta-cell killing: studies from an acute model.

Authors:  Boris Calderon; Anish Suri; Emil R Unanue
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

2.  Heterogeneous lymphokine-activated killer cell precursor populations. Development of a monoclonal antibody that separates two populations of precursors with distinct culture requirements and separate target-recognition repertoires.

Authors:  B A Fox; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Differential effects of various cytokines on the generation of rat LAK cells from their purified precursors.

Authors:  A A Maghazachi
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

4.  Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.

Authors:  Y Kuroki; H Ochiai; M Kurokawa; S Niwayama; C Kishimoto; K Tazawa; M Fujimaki
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

5.  Involvement of cyclic adenosine monophosphate in the interleukin 4 inhibitory effect on interleukin 2-induced lymphokine-activated killer generation.

Authors:  J Y Blay; D Branellec; E Robinet; B Dugas; F Gay; S Chouaïb
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

6.  Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.

Authors:  P Wersäll; G Masucci; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Growth inhibition of Candida albicans by interleukin-2-activated splenocytes.

Authors:  D W Beno; H L Mathews
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

8.  Endogenous interferon alpha/beta produced by Kupffer cells inhibits interleukin-1, tumor necrosis factor alpha production and interleukin-2-induced activation of nonparenchymal liver cells.

Authors:  S P Tzung; S A Cohen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

9.  Induction of lymphokine-activated killer cells from nude mouse spleen cells by interleukin-4.

Authors:  I S Tunru; H Suzuki; M Kobayashi
Journal:  Experientia       Date:  1993-01-15

10.  Effect of recombinant human tumor necrosis factor alpha on the induction of antibody-dependent cellular cytotoxicity in the treatment of established B16 melanoma liver nodules.

Authors:  A Eisenthal; J K McIntosh
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.